- Home
- HBT vs REPL Comparison
HBT vs REPL Comparison
Compare HBT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- REPL
- Stock Information
- Founded
- HBT 1920
- REPL 2015
- Country
- HBT United States
- REPL United States
- Employees
- HBT N/A
- REPL N/A
- Industry
- HBT Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- REPL Health Care
- Exchange
- HBT Nasdaq
- REPL Nasdaq
- Market Cap
- HBT 706.0M
- REPL 578.4M
- IPO Year
- HBT 2019
- REPL 2018
- Fundamental
- Price
- HBT $24.07
- REPL $9.58
- Analyst Decision
- HBT Hold
- REPL Strong Buy
- Analyst Count
- HBT 5
- REPL 6
- Target Price
- HBT $25.25
- REPL $20.00
- AVG Volume (30 Days)
- HBT 26.6K
- REPL 1.6M
- Earning Date
- HBT 07-21-2025
- REPL 05-22-2025
- Dividend Yield
- HBT 3.57%
- REPL N/A
- EPS Growth
- HBT 6.07
- REPL N/A
- EPS
- HBT 2.38
- REPL N/A
- Revenue
- HBT $227,041,000.00
- REPL N/A
- Revenue This Year
- HBT $8.82
- REPL N/A
- Revenue Next Year
- HBT $2.74
- REPL N/A
- P/E Ratio
- HBT $9.83
- REPL N/A
- Revenue Growth
- HBT 1.69
- REPL N/A
- 52 Week Low
- HBT $18.16
- REPL $4.93
- 52 Week High
- HBT $26.25
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- HBT 50.20
- REPL 59.80
- Support Level
- HBT $23.12
- REPL $8.25
- Resistance Level
- HBT $24.44
- REPL $9.53
- Average True Range (ATR)
- HBT 0.61
- REPL 0.90
- MACD
- HBT -0.10
- REPL 0.21
- Stochastic Oscillator
- HBT 35.67
- REPL 90.11
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.